STOCK TITAN

Theratechnologies Inc. - THTX STOCK NEWS

Welcome to our dedicated news page for Theratechnologies (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theratechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theratechnologies's position in the market.

Rhea-AI Summary
Theratechnologies announces FDA's assigned goal date for the approval of tesamorelin's F8 formulation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
Rhea-AI Summary
Theratechnologies reported Q3 2023 consolidated revenue of $20.9 million and adjusted EBITDA of $2.2 million. They submitted the BLA for the F8 formulation of tesamorelin to the FDA. They also reached an agreement in principle on key amendments to their loan facility with Marathon. Revenue growth potential expected from the F8 formulation. Tightened FY2023 revenue guidance to $82-85 million, representing 3-6% growth. Net sales of EGRIFTA SV increased by 2.4% in Q3 2023, while Trogarzo net sales decreased by 3.3%. R&D expenses decreased by 36% in Q3 2023. Selling expenses decreased compared to last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.27%
Tags
-
Rhea-AI Summary
Theratechnologies reaches agreement with Marathon Asset Management to amend credit agreement, including removal of minimum liquidity covenant and change to adjusted EBITDA target
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
Rhea-AI Summary
Theratechnologies files sBLA for F8 formulation of tesamorelin to FDA for review, which is intended to replace EGRIFTA SV® for treatment of excess abdominal fat in adults with HIV and lipodystrophy. F8 formulation is 8 times more concentrated than EGRIFTA® and 2 times more concentrated than F4 formulation, enabling smaller volume of administration. New formulation is patent protected in the U.S. until 2033.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Summary
Theratechnologies CEO to present at Cantor Fitzgerald Global Healthcare Conference 2023 on September 27. CFO also available for investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
Rhea-AI Summary
Theratechnologies Inc. to report Q3 financial results on September 26, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
Rhea-AI Summary
Theratechnologies to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.95%
Tags
conferences
-
Rhea-AI Summary
Theratechnologies expects positive adjusted EBITDA for Q3 2023 and holds US$22.9 million in cash, bonds, and money market funds as of August 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
-
Rhea-AI Summary
Theratechnologies activates all US-based clinical sites for Phase 1 trial of sudocetaxel zendusortide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
Rhea-AI Summary
Paul Lévesque, President and CEO of Hamilton Thorne Ltd., shares his Company's story in an interview with TMX Group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
Theratechnologies Inc.

Nasdaq:THTX

THTX Rankings

THTX Stock Data

65.29M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.